PMC:7463108 / 27117-28163 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T208","span":{"begin":44,"end":49},"obj":"Body_part"},{"id":"T209","span":{"begin":50,"end":55},"obj":"Body_part"},{"id":"T210","span":{"begin":115,"end":122},"obj":"Body_part"},{"id":"T211","span":{"begin":139,"end":146},"obj":"Body_part"},{"id":"T212","span":{"begin":148,"end":151},"obj":"Body_part"},{"id":"T213","span":{"begin":153,"end":175},"obj":"Body_part"},{"id":"T214","span":{"begin":236,"end":239},"obj":"Body_part"},{"id":"T215","span":{"begin":241,"end":260},"obj":"Body_part"},{"id":"T216","span":{"begin":295,"end":305},"obj":"Body_part"},{"id":"T217","span":{"begin":321,"end":338},"obj":"Body_part"},{"id":"T218","span":{"begin":365,"end":368},"obj":"Body_part"},{"id":"T219","span":{"begin":434,"end":441},"obj":"Body_part"},{"id":"T220","span":{"begin":585,"end":588},"obj":"Body_part"},{"id":"T221","span":{"begin":822,"end":839},"obj":"Body_part"}],"attributes":[{"id":"A208","pred":"fma_id","subj":"T208","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A209","pred":"fma_id","subj":"T209","obj":"http://purl.org/sig/ont/fma/fma50801"},{"id":"A210","pred":"fma_id","subj":"T210","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A211","pred":"fma_id","subj":"T211","obj":"http://purl.org/sig/ont/fma/fma61834"},{"id":"A212","pred":"fma_id","subj":"T212","obj":"http://purl.org/sig/ont/fma/fma55675"},{"id":"A213","pred":"fma_id","subj":"T213","obj":"http://purl.org/sig/ont/fma/fma55675"},{"id":"A214","pred":"fma_id","subj":"T214","obj":"http://purl.org/sig/ont/fma/fma20935"},{"id":"A215","pred":"fma_id","subj":"T215","obj":"http://purl.org/sig/ont/fma/fma20935"},{"id":"A216","pred":"fma_id","subj":"T216","obj":"http://purl.org/sig/ont/fma/fma83367"},{"id":"A217","pred":"fma_id","subj":"T217","obj":"http://purl.org/sig/ont/fma/fma61811"},{"id":"A218","pred":"fma_id","subj":"T218","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A219","pred":"fma_id","subj":"T219","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A220","pred":"fma_id","subj":"T220","obj":"http://purl.org/sig/ont/fma/fma84079"},{"id":"A221","pred":"fma_id","subj":"T221","obj":"http://purl.org/sig/ont/fma/fma224850"}],"text":"ABC, abacavir; ARV, antiretroviral(s); BBB, blood-brain barrier; b.i.d., twice a day; Brd4, Bromodomain-containing protein 4; CPu, caudate-putamen; CNS, central nervous system; CPP, conditioned place preference; CM, conditioned medium; CSF, cerebrospinal fluid; DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DRD2L, type 2 dopamine receptor; DTG, dolutegravir; HIVE, HIV encephalitis (typically seen pre-cART); HSPA5, heat shock 70-kDa protein A 5; IDU, injection drug use; i.m., intramuscularly; i.p., intraperitoneal; Iba1, ionized calcium-binding adapter molecule 1; 3TC, lamivudine; MHC class II, major histocompatibility class II; mIPSC, miniature inhibitory postsynaptic currents; MOR, μ-opioid receptor; No info, information not provided or uncertain; OST, opioid substitution therapy; OUD, opioid use disorder; PFC, prefrontal cortex; PENK, preproenkephalin; q.d., once a day; q.i.d., four times a day; ROS, reactive oxygen species; s.c., subcutaneous; SUD, substance use disorder; tg, transgenic; t.i.d., three times a day; ZDV, zidovudine"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T57","span":{"begin":44,"end":63},"obj":"Body_part"},{"id":"T58","span":{"begin":44,"end":49},"obj":"Body_part"},{"id":"T59","span":{"begin":50,"end":55},"obj":"Body_part"},{"id":"T60","span":{"begin":131,"end":146},"obj":"Body_part"},{"id":"T61","span":{"begin":139,"end":146},"obj":"Body_part"},{"id":"T62","span":{"begin":148,"end":151},"obj":"Body_part"},{"id":"T63","span":{"begin":153,"end":175},"obj":"Body_part"},{"id":"T64","span":{"begin":161,"end":175},"obj":"Body_part"},{"id":"T65","span":{"begin":241,"end":260},"obj":"Body_part"},{"id":"T66","span":{"begin":822,"end":839},"obj":"Body_part"},{"id":"T67","span":{"begin":833,"end":839},"obj":"Body_part"}],"attributes":[{"id":"A57","pred":"uberon_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/UBERON_0000120"},{"id":"A58","pred":"uberon_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A59","pred":"uberon_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"A60","pred":"uberon_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/UBERON_0005383"},{"id":"A61","pred":"uberon_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/UBERON_0001874"},{"id":"A62","pred":"uberon_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"A63","pred":"uberon_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"A64","pred":"uberon_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/UBERON_0001016"},{"id":"A65","pred":"uberon_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/UBERON_0001359"},{"id":"A66","pred":"uberon_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/UBERON_0000451"},{"id":"A67","pred":"uberon_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/UBERON_0001851"}],"text":"ABC, abacavir; ARV, antiretroviral(s); BBB, blood-brain barrier; b.i.d., twice a day; Brd4, Bromodomain-containing protein 4; CPu, caudate-putamen; CNS, central nervous system; CPP, conditioned place preference; CM, conditioned medium; CSF, cerebrospinal fluid; DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DRD2L, type 2 dopamine receptor; DTG, dolutegravir; HIVE, HIV encephalitis (typically seen pre-cART); HSPA5, heat shock 70-kDa protein A 5; IDU, injection drug use; i.m., intramuscularly; i.p., intraperitoneal; Iba1, ionized calcium-binding adapter molecule 1; 3TC, lamivudine; MHC class II, major histocompatibility class II; mIPSC, miniature inhibitory postsynaptic currents; MOR, μ-opioid receptor; No info, information not provided or uncertain; OST, opioid substitution therapy; OUD, opioid use disorder; PFC, prefrontal cortex; PENK, preproenkephalin; q.d., once a day; q.i.d., four times a day; ROS, reactive oxygen species; s.c., subcutaneous; SUD, substance use disorder; tg, transgenic; t.i.d., three times a day; ZDV, zidovudine"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T73","span":{"begin":359,"end":363},"obj":"Disease"},{"id":"T74","span":{"begin":365,"end":381},"obj":"Disease"},{"id":"T75","span":{"begin":369,"end":381},"obj":"Disease"}],"attributes":[{"id":"A73","pred":"mondo_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/MONDO_0020689"},{"id":"A74","pred":"mondo_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/MONDO_0020689"},{"id":"A75","pred":"mondo_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"}],"text":"ABC, abacavir; ARV, antiretroviral(s); BBB, blood-brain barrier; b.i.d., twice a day; Brd4, Bromodomain-containing protein 4; CPu, caudate-putamen; CNS, central nervous system; CPP, conditioned place preference; CM, conditioned medium; CSF, cerebrospinal fluid; DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DRD2L, type 2 dopamine receptor; DTG, dolutegravir; HIVE, HIV encephalitis (typically seen pre-cART); HSPA5, heat shock 70-kDa protein A 5; IDU, injection drug use; i.m., intramuscularly; i.p., intraperitoneal; Iba1, ionized calcium-binding adapter molecule 1; 3TC, lamivudine; MHC class II, major histocompatibility class II; mIPSC, miniature inhibitory postsynaptic currents; MOR, μ-opioid receptor; No info, information not provided or uncertain; OST, opioid substitution therapy; OUD, opioid use disorder; PFC, prefrontal cortex; PENK, preproenkephalin; q.d., once a day; q.i.d., four times a day; ROS, reactive oxygen species; s.c., subcutaneous; SUD, substance use disorder; tg, transgenic; t.i.d., three times a day; ZDV, zidovudine"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T295","span":{"begin":44,"end":49},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T296","span":{"begin":44,"end":49},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T297","span":{"begin":50,"end":55},"obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"T298","span":{"begin":50,"end":55},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T299","span":{"begin":79,"end":80},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T300","span":{"begin":148,"end":151},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T301","span":{"begin":148,"end":151},"obj":"http://www.ebi.ac.uk/efo/EFO_0000908"},{"id":"T302","span":{"begin":148,"end":151},"obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"T303","span":{"begin":153,"end":175},"obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"T304","span":{"begin":153,"end":175},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T305","span":{"begin":153,"end":175},"obj":"http://www.ebi.ac.uk/efo/EFO_0000908"},{"id":"T306","span":{"begin":321,"end":329},"obj":"http://purl.obolibrary.org/obo/CHEBI_18243"},{"id":"T307","span":{"begin":442,"end":443},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T308","span":{"begin":833,"end":839},"obj":"http://purl.obolibrary.org/obo/UBERON_0001851"},{"id":"T309","span":{"begin":876,"end":877},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T310","span":{"begin":902,"end":903},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T311","span":{"begin":1024,"end":1025},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"ABC, abacavir; ARV, antiretroviral(s); BBB, blood-brain barrier; b.i.d., twice a day; Brd4, Bromodomain-containing protein 4; CPu, caudate-putamen; CNS, central nervous system; CPP, conditioned place preference; CM, conditioned medium; CSF, cerebrospinal fluid; DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DRD2L, type 2 dopamine receptor; DTG, dolutegravir; HIVE, HIV encephalitis (typically seen pre-cART); HSPA5, heat shock 70-kDa protein A 5; IDU, injection drug use; i.m., intramuscularly; i.p., intraperitoneal; Iba1, ionized calcium-binding adapter molecule 1; 3TC, lamivudine; MHC class II, major histocompatibility class II; mIPSC, miniature inhibitory postsynaptic currents; MOR, μ-opioid receptor; No info, information not provided or uncertain; OST, opioid substitution therapy; OUD, opioid use disorder; PFC, prefrontal cortex; PENK, preproenkephalin; q.d., once a day; q.i.d., four times a day; ROS, reactive oxygen species; s.c., subcutaneous; SUD, substance use disorder; tg, transgenic; t.i.d., three times a day; ZDV, zidovudine"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T209","span":{"begin":0,"end":3},"obj":"Chemical"},{"id":"T210","span":{"begin":5,"end":13},"obj":"Chemical"},{"id":"T211","span":{"begin":115,"end":122},"obj":"Chemical"},{"id":"T212","span":{"begin":177,"end":180},"obj":"Chemical"},{"id":"T213","span":{"begin":262,"end":267},"obj":"Chemical"},{"id":"T214","span":{"begin":287,"end":290},"obj":"Chemical"},{"id":"T215","span":{"begin":321,"end":329},"obj":"Chemical"},{"id":"T217","span":{"begin":345,"end":357},"obj":"Chemical"},{"id":"T218","span":{"begin":434,"end":441},"obj":"Chemical"},{"id":"T219","span":{"begin":462,"end":466},"obj":"Chemical"},{"id":"T220","span":{"begin":532,"end":539},"obj":"Chemical"},{"id":"T222","span":{"begin":556,"end":564},"obj":"Chemical"},{"id":"T223","span":{"begin":568,"end":571},"obj":"Chemical"},{"id":"T224","span":{"begin":573,"end":583},"obj":"Chemical"},{"id":"T225","span":{"begin":595,"end":597},"obj":"Chemical"},{"id":"T226","span":{"begin":630,"end":632},"obj":"Chemical"},{"id":"T227","span":{"begin":817,"end":820},"obj":"Chemical"},{"id":"T228","span":{"begin":909,"end":912},"obj":"Chemical"},{"id":"T229","span":{"begin":914,"end":937},"obj":"Chemical"},{"id":"T230","span":{"begin":923,"end":929},"obj":"Chemical"},{"id":"T231","span":{"begin":1036,"end":1046},"obj":"Chemical"}],"attributes":[{"id":"A209","pred":"chebi_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/CHEBI_421707"},{"id":"A210","pred":"chebi_id","subj":"T210","obj":"http://purl.obolibrary.org/obo/CHEBI_421707"},{"id":"A211","pred":"chebi_id","subj":"T211","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A212","pred":"chebi_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/CHEBI_34603"},{"id":"A213","pred":"chebi_id","subj":"T213","obj":"http://purl.obolibrary.org/obo/CHEBI_272"},{"id":"A214","pred":"chebi_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/CHEBI_15428"},{"id":"A215","pred":"chebi_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/CHEBI_18243"},{"id":"A216","pred":"chebi_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/CHEBI_59905"},{"id":"A217","pred":"chebi_id","subj":"T217","obj":"http://purl.obolibrary.org/obo/CHEBI_76010"},{"id":"A218","pred":"chebi_id","subj":"T218","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A219","pred":"chebi_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A220","pred":"chebi_id","subj":"T220","obj":"http://purl.obolibrary.org/obo/CHEBI_22984"},{"id":"A221","pred":"chebi_id","subj":"T220","obj":"http://purl.obolibrary.org/obo/CHEBI_29320"},{"id":"A222","pred":"chebi_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A223","pred":"chebi_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/CHEBI_63577"},{"id":"A224","pred":"chebi_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/CHEBI_63577"},{"id":"A225","pred":"chebi_id","subj":"T225","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A226","pred":"chebi_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A227","pred":"chebi_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/CHEBI_134091"},{"id":"A228","pred":"chebi_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/CHEBI_26523"},{"id":"A229","pred":"chebi_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/CHEBI_26523"},{"id":"A230","pred":"chebi_id","subj":"T230","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A231","pred":"chebi_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/CHEBI_10110"}],"text":"ABC, abacavir; ARV, antiretroviral(s); BBB, blood-brain barrier; b.i.d., twice a day; Brd4, Bromodomain-containing protein 4; CPu, caudate-putamen; CNS, central nervous system; CPP, conditioned place preference; CM, conditioned medium; CSF, cerebrospinal fluid; DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DRD2L, type 2 dopamine receptor; DTG, dolutegravir; HIVE, HIV encephalitis (typically seen pre-cART); HSPA5, heat shock 70-kDa protein A 5; IDU, injection drug use; i.m., intramuscularly; i.p., intraperitoneal; Iba1, ionized calcium-binding adapter molecule 1; 3TC, lamivudine; MHC class II, major histocompatibility class II; mIPSC, miniature inhibitory postsynaptic currents; MOR, μ-opioid receptor; No info, information not provided or uncertain; OST, opioid substitution therapy; OUD, opioid use disorder; PFC, prefrontal cortex; PENK, preproenkephalin; q.d., once a day; q.i.d., four times a day; ROS, reactive oxygen species; s.c., subcutaneous; SUD, substance use disorder; tg, transgenic; t.i.d., three times a day; ZDV, zidovudine"}

{"project":"LitCovid-PubTator","denotations":[{"id":"804","span":{"begin":86,"end":90},"obj":"Gene"},{"id":"805","span":{"begin":92,"end":124},"obj":"Gene"},{"id":"806","span":{"begin":126,"end":129},"obj":"Gene"},{"id":"807","span":{"begin":409,"end":414},"obj":"Gene"},{"id":"808","span":{"begin":518,"end":522},"obj":"Gene"},{"id":"809","span":{"begin":524,"end":566},"obj":"Gene"},{"id":"810","span":{"begin":685,"end":688},"obj":"Gene"},{"id":"811","span":{"begin":690,"end":707},"obj":"Gene"},{"id":"812","span":{"begin":757,"end":760},"obj":"Gene"},{"id":"813","span":{"begin":841,"end":845},"obj":"Gene"},{"id":"814","span":{"begin":847,"end":863},"obj":"Gene"},{"id":"815","span":{"begin":236,"end":239},"obj":"Gene"},{"id":"816","span":{"begin":992,"end":1002},"obj":"Species"},{"id":"817","span":{"begin":365,"end":381},"obj":"Disease"}],"attributes":[{"id":"A804","pred":"tao:has_database_id","subj":"804","obj":"Gene:23476"},{"id":"A805","pred":"tao:has_database_id","subj":"805","obj":"Gene:23476"},{"id":"A806","pred":"tao:has_database_id","subj":"806","obj":"Gene:1361"},{"id":"A807","pred":"tao:has_database_id","subj":"807","obj":"Gene:3309"},{"id":"A808","pred":"tao:has_database_id","subj":"808","obj":"Gene:199"},{"id":"A809","pred":"tao:has_database_id","subj":"809","obj":"Gene:199"},{"id":"A810","pred":"tao:has_database_id","subj":"810","obj":"Gene:4988"},{"id":"A811","pred":"tao:has_database_id","subj":"811","obj":"Gene:4988"},{"id":"A812","pred":"tao:has_database_id","subj":"812","obj":"Gene:1650"},{"id":"A813","pred":"tao:has_database_id","subj":"813","obj":"Gene:5179"},{"id":"A814","pred":"tao:has_database_id","subj":"814","obj":"Gene:5179"},{"id":"A815","pred":"tao:has_database_id","subj":"815","obj":"Gene:3918"},{"id":"A816","pred":"tao:has_database_id","subj":"816","obj":"Tax:10090"},{"id":"A817","pred":"tao:has_database_id","subj":"817","obj":"MESH:D004660"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ABC, abacavir; ARV, antiretroviral(s); BBB, blood-brain barrier; b.i.d., twice a day; Brd4, Bromodomain-containing protein 4; CPu, caudate-putamen; CNS, central nervous system; CPP, conditioned place preference; CM, conditioned medium; CSF, cerebrospinal fluid; DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DRD2L, type 2 dopamine receptor; DTG, dolutegravir; HIVE, HIV encephalitis (typically seen pre-cART); HSPA5, heat shock 70-kDa protein A 5; IDU, injection drug use; i.m., intramuscularly; i.p., intraperitoneal; Iba1, ionized calcium-binding adapter molecule 1; 3TC, lamivudine; MHC class II, major histocompatibility class II; mIPSC, miniature inhibitory postsynaptic currents; MOR, μ-opioid receptor; No info, information not provided or uncertain; OST, opioid substitution therapy; OUD, opioid use disorder; PFC, prefrontal cortex; PENK, preproenkephalin; q.d., once a day; q.i.d., four times a day; ROS, reactive oxygen species; s.c., subcutaneous; SUD, substance use disorder; tg, transgenic; t.i.d., three times a day; ZDV, zidovudine"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T45","span":{"begin":182,"end":210},"obj":"http://purl.obolibrary.org/obo/GO_1990708"}],"text":"ABC, abacavir; ARV, antiretroviral(s); BBB, blood-brain barrier; b.i.d., twice a day; Brd4, Bromodomain-containing protein 4; CPu, caudate-putamen; CNS, central nervous system; CPP, conditioned place preference; CM, conditioned medium; CSF, cerebrospinal fluid; DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DRD2L, type 2 dopamine receptor; DTG, dolutegravir; HIVE, HIV encephalitis (typically seen pre-cART); HSPA5, heat shock 70-kDa protein A 5; IDU, injection drug use; i.m., intramuscularly; i.p., intraperitoneal; Iba1, ionized calcium-binding adapter molecule 1; 3TC, lamivudine; MHC class II, major histocompatibility class II; mIPSC, miniature inhibitory postsynaptic currents; MOR, μ-opioid receptor; No info, information not provided or uncertain; OST, opioid substitution therapy; OUD, opioid use disorder; PFC, prefrontal cortex; PENK, preproenkephalin; q.d., once a day; q.i.d., four times a day; ROS, reactive oxygen species; s.c., subcutaneous; SUD, substance use disorder; tg, transgenic; t.i.d., three times a day; ZDV, zidovudine"}

{"project":"LitCovid-sentences","denotations":[{"id":"T407","span":{"begin":0,"end":1046},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ABC, abacavir; ARV, antiretroviral(s); BBB, blood-brain barrier; b.i.d., twice a day; Brd4, Bromodomain-containing protein 4; CPu, caudate-putamen; CNS, central nervous system; CPP, conditioned place preference; CM, conditioned medium; CSF, cerebrospinal fluid; DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DRD2L, type 2 dopamine receptor; DTG, dolutegravir; HIVE, HIV encephalitis (typically seen pre-cART); HSPA5, heat shock 70-kDa protein A 5; IDU, injection drug use; i.m., intramuscularly; i.p., intraperitoneal; Iba1, ionized calcium-binding adapter molecule 1; 3TC, lamivudine; MHC class II, major histocompatibility class II; mIPSC, miniature inhibitory postsynaptic currents; MOR, μ-opioid receptor; No info, information not provided or uncertain; OST, opioid substitution therapy; OUD, opioid use disorder; PFC, prefrontal cortex; PENK, preproenkephalin; q.d., once a day; q.i.d., four times a day; ROS, reactive oxygen species; s.c., subcutaneous; SUD, substance use disorder; tg, transgenic; t.i.d., three times a day; ZDV, zidovudine"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T37","span":{"begin":369,"end":381},"obj":"Phenotype"},{"id":"T38","span":{"begin":421,"end":426},"obj":"Phenotype"}],"attributes":[{"id":"A37","pred":"hp_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/HP_0002383"},{"id":"A38","pred":"hp_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/HP_0031273"}],"text":"ABC, abacavir; ARV, antiretroviral(s); BBB, blood-brain barrier; b.i.d., twice a day; Brd4, Bromodomain-containing protein 4; CPu, caudate-putamen; CNS, central nervous system; CPP, conditioned place preference; CM, conditioned medium; CSF, cerebrospinal fluid; DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DRD2L, type 2 dopamine receptor; DTG, dolutegravir; HIVE, HIV encephalitis (typically seen pre-cART); HSPA5, heat shock 70-kDa protein A 5; IDU, injection drug use; i.m., intramuscularly; i.p., intraperitoneal; Iba1, ionized calcium-binding adapter molecule 1; 3TC, lamivudine; MHC class II, major histocompatibility class II; mIPSC, miniature inhibitory postsynaptic currents; MOR, μ-opioid receptor; No info, information not provided or uncertain; OST, opioid substitution therapy; OUD, opioid use disorder; PFC, prefrontal cortex; PENK, preproenkephalin; q.d., once a day; q.i.d., four times a day; ROS, reactive oxygen species; s.c., subcutaneous; SUD, substance use disorder; tg, transgenic; t.i.d., three times a day; ZDV, zidovudine"}